Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 4/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741651 | 0.94 | JAK2 (0.32) | MEN1KMT2AS1PR4JAK2JAK3 | |
| SCHEMBL6740758 | 0.87 | KDM4E (0.36) | KMT2AALDH1A1GAAEGFR | |
| SCHEMBL6741831 | 0.87 | TSHR (0.36) | MEN1KMT2AS1PR4ALDH1A1GAA | |
| SCHEMBL6742101 | 0.85 | ALDH1A1 (0.40) | MEN1KMT2AALDH1A1PRKCQ | |
| SCHEMBL6882952 | 0.85 | ALDH1A1 (0.31) | ALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL6882939 | 0.85 | ALDH1A1 (0.31) | ALDH1A1GAA | |
| SCHEMBL6739562 | 0.84 | CHRM4 (0.37) | MEN1KMT2AS1PR4ALDH1A1GAA | |
| SCHEMBL6744446 | 0.84 | SMN1; SMN2 (0.38) | MEN1KMT2AALDH1A1GAAPRKCQ | |
| SCHEMBL6741846 | 0.83 | ALDH1A1 (0.40) | KMT2AALDH1A1GAAPRKCQ | |
| SCHEMBL6745661 | 0.83 | KDM4E (0.34) | KMT2AALDH1A1GAAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818642-B2 | CAMPYLOBACTER INFECTION TREATMENT | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040152714-A1 | Benzylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152714-A1 | Benzylaminopyrimidines | DPYD, PGLS, TPMT | RIPK1 4735/4885MEN1 2577/4885KMT2A 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.